Smartlens Inc. has announced the close of an oversubscribed $5.2 million bridge financing round led by Ambit Health Ventures. The funding will support the company’s US Food and Drug Administration (FDA) clearance process and preparation for the commercial launch of its miLens platform.

miLens is an electronics-free contact lens technology that is capable of continuous intraocular pressure (IOP) monitoring. Designed as a soft, wearable microfluidic lens, miLens captures subtle pressure fluctuations throughout the day and night to provide continuous, real-world IOP data in patients with glaucoma and ocular hypertension, as well as those who need postoperative IOP monitoring. The device integrates with Smartlens’ artificial intelligence-powered smartphone imaging platform, which analyzes captured data to inform treatment optimization.

Building on progress in its multisite US pivotal trial, Smartlens has made significant advancements in regulatory preparation, manufacturing scale-up, and clinical validation. An independent double-blind survey of 166 ophthalmic practitioners conducted by Market Scope found that 96.2% expressed intent to adopt the technology once available.